Nur-Sultan, Kazakhstan: Well on the way to an effective HTA process...
...and a white Christmas
BLOG
- Dec 12, 2019
Health Technology Assessment: Cost-effectiveness thresholds vary and are rarely explicit...
...yet, most health care systems have adopted cost effectiveness ratios to make decisions on the allocation of health care resources....
- Dec 11, 2019
Vienna School of Clinical Research: Health Technology Assessment goes Kazakhstan
On the way to equitable and affordable healthcare systems: Vienna School of Clinical Research provides academic training & support...
- Nov 28, 2019
EU regulatory pathways (II): all processes lead to Market Authorization decisions...
...but which one is most suited to YOUR products? Interested? Contact us!
- Nov 28, 2019
EU regulatory pathways (I): All pathways lead to...
...a Market Authorization decision...but which one is the fastest & most cost effective? Interested? Contact us!
- Nov 20, 2019
The evolution of reimbursement: evidence based medicine wins over non-proven therapeutics
Interested? Contact us!
- Nov 13, 2019
Scientific communication (2): does your narrative reach opinion makers?
Contact us to discuss how we can help you with your scientific communication
- Nov 13, 2019
Scientific communication (1): do you monitor what they say about you?
Contact us to discuss how we can help you with your scientific communication
- Oct 30, 2019
Different systems have different HTA needs
Vienna School of Clinical Research: tailoring HTA curriculums to participants' needs
- Oct 24, 2019
German healthcare system October 2019*: increasing number of non available prescription drugs: drive
...the fact that the downwards pricing spiral leads to supply situations in which the negotiation balance tips to monopoly pharma...
- Oct 17, 2019
Biosimilars: automatic substitution rules create new doctor - patient interaction challenges.
Treatment decisions should always be the result of an informed doctor - patient interaction in which the doctor keeps final prescription...
- Oct 10, 2019
Biosimilars: Are reference analogs and biosimilars interchangeable?
In the field of i.e. Diabetes therapy, the Insulin biosimilar interchangeability and switching discussion is by lack of data from...
- Oct 2, 2019
Pharmaceutical innovation: what’s the deal and what are outcome assumptions…
...that need to be factored into early clinical development decision making by backwards engineering the required health outcome data...
- Sep 19, 2019
VSCR-SFU Health outcome research course- evidence-based decision making for pricing and reimbursemen
New diploma course series (university course) for managers of the pharmaceutical and medical technology industry (market access,...
- Sep 15, 2019
Technology is there to help enable more meaningful and empathic patient-doctor relationships...
...so that algorithms free up time to discuss diagnosis and treatment options and shift the focus on to the human interaction. Suggested...
- Sep 4, 2019
AI and big data are big in big pharma...
...probably not yet a spaceship to new pharma horizons - but it's clearly taking off! #BigData #BigPharma #Pharmamarket
- Aug 30, 2019
The family tree of pharmaceutical pricing is in full bloom...
...and winning strategies translate relevant medical data into meaningful value propositions for payers' budgetary planning security....
- Aug 19, 2019
Pharmaceuticals change from drugs to therapeutics to solutions...
...and healthcare systems expect from the industry to deliver more... #Personalizedmedicine #Therapies #Treatmentconcepts